

25th May, 2022

To
BSE Limited
Department of Corporate Services,
Phiroze Jeejeebhoy Towers, Dalal Street,
Mumbai 400001.
BSE Scrip Code: 533014

Dear Sir/Madam,

Sub: Outcome of the Board Meeting

In continuation of our letter dated 18th May 2022, we wish to inform you that the Board of Directors of the Company at its meeting held on 25.05.2022 has inter alia

1. Approved the Audited Financial Results (both Standalone & Consolidated) of the Company for the quarter and year ended 31st March 2022.
2. Recommended equity dividend at 2.5% (25 paise per share) for the financial year 2021-22, subject to the approval of shareholders at the ensuing 18th Annual General Meeting (AGM).

Pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, copies of the aforesaid audited financial results together with the report of auditors are enclosed herewith.

The Board of Directors, at its meeting held today, has also considered and recommended the following, subject to the approval of shareholders at the ensuing 18th AGM:

1. Re-appointment of M/s. SRSV and Associates, Chartered Accountants as the Statutory Auditors for a second term of 5 consecutive years (ie. from the conclusion of 18th AGM till the conclusion of the 23rd AGM of the Company), based on the recommendation of Audit Committee.
2. Re-appointment of Mrs. Rita Chandrasekar (DIN: 03013549) as Independent Director of the Company for further period of 5 years w.e.f 27th June 2022, based on the recommendation of Nomination & Remuneration Committee.

The above intimations may kindly be taken on record.

Thanking You,

Yours faithfully,
For Sicagen India Limited



R Chandrasekar
Whole Time Director



Encl: a/a

Sicagen India Ltd.

Registered & Corporate Office:

4th Floor, SPIC House, 88, Mount Road, Guindy, Chennai 600 032 INDIA

Tel: +91 44 4075 4075 | Fax: +91 44 4075 4099 | info@sicagen.com

CIN No.: L74900TN2004PLC053467 | www.sicagen.com